Opinion

Video

Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

Author(s):

Robert Z. Orlowski, MD, PhDJonathan L. Kaufman, MD

The key opinion leaders provide essential insights and recommendations for community oncologists to enhance and optimize treatment strategies for their patients with relapsed/refractory multiple myeloma.

Video content above is prompted by the following:

  • What are some key takeaways you wish to offer community oncologists?
Related Videos
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Suzanne Lentzsch, MD, PhD
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Rahul Banerjee, MD, FACP
Ajai Chari, MD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Binod Dhakal, MD
Related Content
Eric Jonasch, MD, physician, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
October 14th 2024

NKT2152 Generates Responses in Heavily Pretreated Advanced ccRCC

Guillermo Garcia-Manero, MD, professor, chief, section of Myelodysplastic Syndromes, deputy chair, Translational Research, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
August 19th 2024

Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond

Jacqueline Brown, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine; associate medical director, Ambulatory Infusion Center, Winship Cancer Institute of Emory University
October 11th 2024

Cisplatin’s Prevalence in Bladder Cancer Falters With the Introduction of Enfortumab Vedotin

Shannon N. Westin, MD, MPH, FACOG, professor, clinical medical director, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center
August 15th 2024

FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer

Jacqueline Brown, MD, of Winship Cancer Institute
October 10th 2024

Enfortumab Vedotin Plus Pembrolizumab Stands Strong as the Frontline Bladder Cancer SOC

Elias Jabbour, MD
October 10th 2024

Tailored Approaches to TKI Dosing Allow for Treatment-Free Remissions and Reduced Toxicity in CML